3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Transitional Cell
25
Urinary Bladder Neoplasms
23
Ureteral Neoplasms
8
Urologic Neoplasms
4
Urethral Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Urogenital Neoplasms
2
Neoplasm Metastasis
2
Muscle Invasive Bladder Urothelial Carcinoma
2
Metastatic Urothelial Cancer
2
Carcinoma, Renal Cell
2
Advanced Bladder Cancer
2
Urothelial Cancer
1
Urologic Diseases
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Urachal adenocarcinoma
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Peripheral Nervous System Diseases
1
Penile Squamous Cell Carcinoma (PSCC)
1
Penile Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Muscle-invasive Bladder Cancer
1
Metastatic Urothelial Cancer and Other Malignant Solid Tumors
1
Metastatic Castration-resistant Prostate Cancer
1
Male Urogenital Diseases
1
Female Urogenital Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
padeliporfin
5
Lycopene
3
pembrolizumab
2
darolutamide
2
Vitamin E
2
Tea
2
Selenium
2
Cholecalciferol
2
relatlimab
1
palladium-bacteriopheophorbide
1
olaparib
1
gedatolisib
1
enfortumab vedotin
1
Therapeutics
1
Sugars
1
Radiation Dose Hypofractionation
1
Pluvicto
1
Nivolumab
1
Mitomycin
1
Intraoperative Neurophysiological Monitoring
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
CP protocol
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Male Urogenital Diseases
×
enfortumab vedotin
×
Genitourinary
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled